Cargando…
The Treatment Based on Ruxolitinib and Amphotericin B is Effective for Relapsed Leishmaniasis-Related Hemophagocytic Lymphohistiocytosis: A Case Report and Literature Review
BACKGROUND: Hemophagocytic lymphohistiocytosis (HLH) is known as a life-threatening syndrome, and Leishmania is the most common protozoan that triggers infection-related HLH. It is thus important to find the root cause and treat it effectively. CASE REPORT: This paper reports a 44-year-old man who d...
Autores principales: | Cui, Tingting, Wang, Jingshi, Wang, Zhao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9664932/ https://www.ncbi.nlm.nih.gov/pubmed/36386416 http://dx.doi.org/10.2147/IDR.S384628 |
Ejemplares similares
-
Successful resolution of hemophagocytic lymphohistiocytosis during the chemotherapy course of acute myelocytic leukemia with ruxolitinib
por: Song, Yue, et al.
Publicado: (2022) -
The Outcome of Induction Therapy for EBV-Related Hemophagocytic Lymphohistiocytosis: A Model for Risk Stratification
por: Cui, Tingting, et al.
Publicado: (2022) -
Dose-escalating ruxolitinib for refractory hemophagocytic lymphohistiocytosis
por: Song, Yue, et al.
Publicado: (2023) -
Use of the JAK Inhibitor Ruxolitinib in the Treatment of Hemophagocytic Lymphohistiocytosis
por: Keenan, Camille, et al.
Publicado: (2021) -
Case of hemophagocytic lymphohistiocytosis with leishmaniasis
por: Chandra, Harish, et al.
Publicado: (2015)